-+ 0.00%
-+ 0.00%
-+ 0.00%

Precipio Q4 2025 Preliminary Revenue $6.7M, An Increase Of 23% From $5.4M YoY

Benzinga·02/25/2026 14:33:20
Listen to the news

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025.

Below are some of the key financial performance metrics for the Company.

  1. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024.



     
  2. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please see a more detailed explanation Adjusted EBITDA at the bottom of this press release.



     
  3. Positive operating cash flow - Precipio will report $368K of positive operating cash flow during Q4-2025, and a total of $688K for 2025. This is compared to $439K of cash generated from operations in 2024. These amounts include certain unusual items related to Change Healthcare transactions and the COVID-related Employee Retention Credit. Excluding the unusual items, the Company's adjusted operating cash flow was $617K for Q4-2025 and a total of $727K for 2025.